Marksans Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its product Exemestane 25mg film-coated tablet.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma has announced that its wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Exemestane 25mg film-coated tablets. Exemestane is a generic oncology drug commonly used in the treatment of breast cancer in postmenopausal women. This approval allows Relonchem to market the product in the UK. The move strengthens Marksans' presence in the UK generics market and adds to its oncology product portfolio alongside its existing therapeutic segments in CVS, CNS, anti-diabetic, and pain management.
Positive for shareholders — the UK MHRA approval enables commercial launch of an oncology generic in a regulated market, adding a new revenue stream. However, the actual financial impact depends on the scale of UK sales, which is not disclosed in this announcement.